Not all people with CLL require therapy. Regardless of all latest improvements, the iwCLL even now suggests watchful observation for individuals with asymptomatic condition.86 This recommendation is based on at least two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).10